Due to non-invasive imaging and the multimodality of magnetic resonance imaging (MRI) images, MRI-based multi-modal brain tumor segmentation (MBTS) studies have attracted more and more attention in recent years. With the great success of convolutional neural networks in various computer vision tasks, lots of MBTS models have been proposed to address the technical challenges of MBTS. However, the problem of limited data collection usually exists in MBTS tasks, making existing studies typically have difficulty in fully exploring the multi-modal MRI images to mine complementary information among different modalities.We propose a novel quaternion mutual learning strategy (QMLS), which consists of a voxel-wise lesion knowledge mutual learning mechanism (VLKML mechanism) and a quaternion multi-modal feature learning module (QMFL module). Specifically, the VLKML mechanism allows the networks to converge to a robust minimum so that aggressive data augmentation techniques can be applied to expand the limited data fully. In particular, the quaternion-valued QMFL module treats different modalities as components of quaternions to sufficiently learn complementary information among different modalities on the hypercomplex domain while significantly reducing the number of parameters by about 75%.Extensive experiments on the dataset BraTS 2020 and BraTS 2019 indicate that QMLS achieves superior results to current popular methods with less computational cost.We propose a novel algorithm for brain tumor segmentation task that achieves better performance with fewer parameters, which helps the clinical application of automatic brain tumor segmentation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/1361-6560/ad135e | DOI Listing |
J Clin Neurophysiol
October 2024
Department of Neurological Surgery, Faculty of Medicine, Demiroglu Bilim University, Istanbul, Turkiye.
Purpose: This study aims to show the impact of multimodal intraoperative neurophysiologic monitoring (IOM) in glioma surgery in preventing severe neurologic injury and increasing tumor removal by comparing the historical cases where IOM was not used.
Methods: Fifty-nine patients with glial tumors located nearby the eloquent area, operated by the same surgeon, were included in the study. Between 2008 and 2012, 21 patients were operated on without IOM (non-IOM); between 2018 and 2021, 38 patients were operated on with IOM.
Bioconjug Chem
January 2025
Guangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China.
Nanobodies play an increasingly prominent role in cancer imaging and therapy. However, their efficacy is often constrained by inadequate tumor penetration and rapid clearance from the bloodstream, particularly in brain tumors due to the intractable blood-brain barrier (BBB). Glycosylation is a favorable strategy for modulating the biological functions of nanobodies, including permeability and pharmacokinetics, but it also leads to heterogeneous glycan structures, which affect the targeting ability, stability, and quality of nanobodies.
View Article and Find Full Text PDFINhibitor of Growth (ING1-5) proteins are epigenetic readers that target histone acetyltransferase (HAT) or histone deacetylase (HDAC) complexes to the H3K4Me3 mark of active transcription. ING5 targets Moz/Morf and HBO1 HAT complexes that alter acetylation of H3 and H4 core histones, affecting gene expression. Previous experiments in vitro indicated that ING5 functions to maintain stem cell character in normal and in cancer stem cells.
View Article and Find Full Text PDFFuture Oncol
January 2025
Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, USA.
Seizures are a frequent complication in glioma. Incidence of brain tumor-related epilepsy (BTRE) in high-grade glioma (HGG) is an estimated > 25% and in low-grade glioma (LGG) is approximately 72%. Two first-line antiseizure medications (ASMs) for BTRE include levetiracetam (LEV) and valproic acid (VPA).
View Article and Find Full Text PDFCurr Neurol Neurosci Rep
January 2025
Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, 80 Avenue Augustin Fliche, Montpellier, 34295, France.
Purpose Of Review: In low-grade glioma (LGG), besides the patient's neurological status and tumor characteristics on neuroimaging, current treatment guidelines mainly rely on the glioma's genetics at diagnosis to define therapeutic strategy, usually starting with surgical resection. However, this snapshot in time does not take into account the antecedent period of tumor progression and its interactions with the brain before presentation. This article reviews new concepts that pertain to reconstruct the history of previous interplay between the LGG's course and adaptive changes in the connectome within which the glioma is embedded over the years preceding the diagnosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!